The central challenge the team set out to address is a familiar one in regenerative medicine. Stem cells delivered into a defect are often metabolically unprepared for the hostile environment they encounter, remaining incompletely committed to the correct lineage and vulnerable to inflammatory and mechanical stress. Cartilage repair is especially unforgiving, because success requires not just cell survival but stable activation of a chondrogenic program, rich deposition of type II collagen and aggrecan, and active suppression of the fibrotic, hypertrophic and matrix-degrading pathways that cause engineered tissue to fail. Conventional approaches rely on biochemical cues such as transforming growth factor-β, which can switch on chondrogenic genes but provide little control over the intracellular metabolic state that must sustain durable matrix production over time.

The researchers’ strategy targets mitochondria, which have increasingly been recognized not as passive power plants but as active arbiters of stem-cell destiny. Mitochondrial membrane potential, respiratory activity, ATP availability and redox tone collectively determine whether a stem cell is merely alive or genuinely competent to regenerate tissue. Red light around 660 nanometers is absorbed by mitochondrial photoacceptors, most notably cytochrome c oxidase, also known as respiratory complex IV, linking photon input directly to electron transport, ATP synthesis and redox signaling. Unlike soluble biochemical factors, light can be applied externally, withdrawn instantly and spatially controlled, making it an attractive tool for preconditioning cells before they are ever placed inside a patient.

To find the right dose, the team systematically tested 5, 15 and 30 joules per square centimeter of 660-nanometer LED light on rabbit BMSCs, using a power density of 50 milliwatts per square centimeter and carefully monitoring culture temperature with infrared thermal imaging to rule out nonspecific heating. The results revealed a classic biphasic dose-response. At 15 joules per square centimeter, the cells proliferated most vigorously, showed increased S-phase entry by flow cytometry, and maintained high viability. The lowest dose produced only a modest effect, while the highest dose failed to enhance proliferation further and actually reduced cellular activity. Notably, a temperature-matched control group that experienced the same warming without light did not reproduce the inhibition seen at the high dose, indicating that the effect was photobiological rather than thermal.

The critical question was whether this proliferative boost translated into genuine chondrogenic commitment. When BMSCs were formed into cartilage pellets and irradiated daily for 14 days, the 15-joule group produced pellets that were larger, more regular and more compact than any other group. Histological staining showed denser tissue organization and stronger proteoglycan deposition, and biochemical assays confirmed elevated total collagen, type II collagen and glycosaminoglycan content. Crucially, when matrix production was normalized to DNA content, the ratios remained highest in the irradiated group, demonstrating that light enhanced the biosynthetic output of each cell rather than simply expanding the cell population. Western blotting revealed increased SOX9, type II collagen and aggrecan, while the unwanted markers COL1A1, COL10A1, RUNX2 and MMP13, which signal fibrosis, hypertrophy and matrix degradation, were all reduced at both protein and mRNA levels.

The mechanistic heart of the study lies in its dissection of the mitochondrial signaling cascade. At the optimal dose, LED irradiation elevated mitochondrial membrane potential, produced a more interconnected mitochondrial network, increased ATP production and enhanced respiratory parameters including basal respiration, ATP-linked respiration, maximal respiration and spare respiratory capacity, as measured by Seahorse extracellular flux analysis. Cytochrome c oxidase activity was also increased. Perhaps most intriguingly, the treatment induced a moderate rise in mitochondrial hydrogen peroxide, a controlled burst of reactive oxygen species that appears to function as a signaling mediator rather than a damaging by-product. At 30 joules per square centimeter, by contrast, ROS accumulation became excessive, accompanied by elevated malondialdehyde and 4-hydroxynonenal, hallmarks of oxidative stress and lipid peroxidation.

Using a panel of pharmacological inhibitors, the researchers traced the pathway from mitochondria to the nucleus. Scavenging ROS with N-acetyl-L-cysteine attenuated the phosphorylation of PI3K, Akt, mTOR and GSK3β, placing moderate mitochondrial ROS upstream of the cascade. Inhibiting PI3K with LY294002 or Akt with MK-2206 suppressed downstream phosphorylation and reduced SOX9, type II collagen and aggrecan expression, while the mTOR inhibitor rapamycin blunted glycosaminoglycan deposition. The enhanced inhibitory phosphorylation of GSK3β, which reduces its negative regulatory activity, further supported SOX9 nuclear activation, confirmed by immunofluorescence showing stronger nuclear SOX9 signal in irradiated cells. Together, these experiments establish the PI3K/Akt/mTOR/GSK3β–SOX9 axis as the conduit through which photonic energy is converted into a chondrogenic transcriptional program.

The team then translated the optimized treatment into a tissue-engineering construct. Egg white-derived biomaterial was fabricated into ring-shaped porous scaffolds, seeded with BMSCs and irradiated for 14 days before implantation into a rabbit tracheal defect created by resecting one native cartilage ring. At 30 days after surgery, bronchoscopic evaluation showed higher airway patency, reduced granulation formation, lower stenosis and less collapse in the 15-joule group compared with untreated and high-dose controls. Histology revealed organized, proteoglycan-rich cartilage-like matrix, and biochemical analysis showed markedly increased GAG/DNA and COL II/DNA levels that approached, though did not fully reach, those of native tracheal tissue. Fibrotic, hypertrophic and matrix-degrading markers were suppressed in vivo, and epithelial repair was improved, with restored basal coverage and ciliated differentiation alongside reduced injury-associated mucus-producing remodeling.

Most compellingly, direct mechanical benchmarking against native trachea showed that the reconstructed rings in the 15-joule group exhibited higher radial compression modulus, greater anti-collapse pressure, improved bending recovery and lower residual deformation than the other groups, with all four parameters shifting toward the native range. The trachea depends on its cartilage rings to resist collapse during every breath, so restoring load-bearing function is the ultimate test of any repair strategy. The irradiated constructs also resisted osteogenic drift, showing no increase in osteocalcin at the optimized dose, while the high-dose group did, reinforcing the importance of precise photonic dosing. The researchers caution that the 30-day observation period was short, that a temperature-matched control specifically matching the 15-joule condition was not included, and that genetic approaches would further strengthen causal interpretation of the signaling pathway.

What distinguishes this work from earlier photobiomodulation studies is its conceptual shift. Previous efforts applied light directly to injured tissues to modulate the local repair environment; here, light is used before implantation to write a regenerative metabolic state into the cells themselves. The 15-joule condition represents a functional window that coordinates mitochondrial activation with cellular adaptation, highlighting that the goal is not maximal ROS production but a favorable bioenergetic-redox balance. The treatment also showed immunomodulatory promise, shifting macrophages from an inflammatory M1-like phenotype toward a reparative M2-like state and preserving chondrogenic gene expression under interleukin-1β challenge, a scenario that mirrors the inflammatory milieu of real wounds. If the approach can be adapted to larger animal models and clinically relevant reconstruction scenarios, externally controlled, growth factor-sparing photonic preconditioning could become a practical and elegant tool for engineering cartilage that not only fills a defect but performs the mechanical work the body demands of it.

Subject of Research: 660 nm LED mitochondrial preconditioning of bone marrow-derived mesenchymal stem cells for functional tracheal cartilage regeneration

Article Title: 660 nm LED preconditioning programs mitochondrial signaling in BMSCs for functional tracheal cartilage regeneration

Article References: An, Z., Zhang, J., Wang, C., She, Y., Xu, Y., Zhou, H., Xia, J., Guo, L., Ma, M., & Zhang, L. (2026). 660 nm LED preconditioning programs mitochondrial signaling in BMSCs for functional tracheal cartilage regeneration. Materials Today Bio, 41, Article 103729. https://doi.org/10.1016/j.mtbio.2026.103729

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103729

Keywords: photobiomodulation, 660 nm LED, mesenchymal stem cells, mitochondria, chondrogenesis, tracheal cartilage, tissue engineering, SOX9, PI3K/Akt/mTOR signaling, reactive oxygen species, cytochrome c oxidase, scaffold

To understand why the discovery matters, it helps to start with the biology of protein turnover. Inside every cell, proteins that are damaged, misfolded or simply no longer needed are tagged with small molecules called ubiquitin, a molecular label that condemns them to destruction by the proteasome, the cell’s waste-disposal complex. Deubiquitinating enzymes, or DUBs, do the opposite: they snip ubiquitin tags off proteins, rescuing them from degradation and extending their functional lifespan. When this balancing act goes wrong, proteins that should be cleared can accumulate to abnormal levels, and in cancer that often means proteins that drive uncontrolled growth are granted an unnatural stay of execution. USP12 belongs to the ubiquitin-specific protease family, and previous work has linked it to several cancers, but its role in ovarian cancer had remained poorly defined.

The identity of its partner in this study was equally obscure. TBC1D22A is a member of the TBC1 domain family, proteins that act as GTPase-activating proteins for Rab GTPases, the molecular switches that regulate vesicle trafficking, membrane trafficking and intracellular transport. While Rab proteins have increasingly been implicated in tumor progression, TBC1D22A’s specific oncogenic mechanisms in ovarian cancer, and crucially the upstream pathways that regulate it, had never been reported. The new study set out to fill that gap by asking a deceptively simple question: what keeps TBC1D22A stable inside ovarian cancer cells, and what happens when that stability is disrupted?

The answer emerged from an unbiased hunt for TBC1D22A’s molecular companions. Using liquid chromatography coupled with tandem mass spectrometry, or LC-MS/MS, the researchers screened for proteins that physically associate with TBC1D22A, and USP12 surfaced as a candidate interacting deubiquitinase. The team then confirmed the partnership through complementary techniques: co-immunoprecipitation experiments showed that the two proteins can be pulled down together from cell lysates, while immunofluorescence co-localization assays revealed that they occupy overlapping territories within the cell. Together, these approaches established that the association is not a fleeting accident of cellular crowding but a genuine physical interaction, the kind that can support a regulatory relationship.

With the interaction confirmed, the researchers moved on to the central mechanistic question: does USP12 actually control how much TBC1D22A exists inside a cell, and if so, how? The evidence points firmly to post-translational regulation. Cycloheximide chase experiments, which block new protein synthesis and allow researchers to watch existing proteins decay over time, showed that TBC1D22A degraded more slowly when USP12 was present. Proteasome inhibition assays demonstrated that TBC1D22A’s destruction proceeds through the ubiquitin-proteasome pathway. Most tellingly, in vivo ubiquitination assays revealed that USP12 directly reduces the ubiquitin load carried by TBC1D22A, effectively stripping off the degradation tags before the proteasome can act. Importantly, USP12 did not alter TBC1D22A transcription, meaning the enzyme works purely at the protein level, preserving existing TBC1D22A molecules rather than coaxing the gene to make more.

That stabilization has consequences. Through a series of gain-of-function and loss-of-function experiments, the team showed that USP12 promotes ovarian cancer cell proliferation, migration and invasion, and that these effects depend on TBC1D22A. When the researchers removed USP12, TBC1D22A levels fell and the cancer cells became less motile and less invasive; when they re-introduced TBC1D22A in rescue experiments, the aggressive behavior returned. This dependency is the crucial detail: it means USP12 is not simply a general growth promoter acting through many parallel routes, but a specific upstream regulator whose oncogenic influence flows through TBC1D22A. Depleting the downstream partner effectively neutralizes the upstream enzyme, which is exactly the kind of linear dependency that makes a signaling axis attractive as a drug target.

The signaling pathway connecting the pair to malignancy is one of the most famous in all of cancer biology. The PI3K-AKT-mTOR cascade integrates signals from growth factor receptors and relays them to the cell’s growth and survival machinery, promoting metabolism, protein synthesis, proliferation and resistance to cell death. It is hyperactivated in a large fraction of human tumors, including ovarian cancers, and has been the subject of intense pharmaceutical interest for decades. In this study, the USP12-TBC1D22A axis was associated with activation of this pathway, providing a plausible mechanistic bridge between a vesicle-trafficking regulator and the malignant phenotype. The researchers also validated their findings in vivo using subcutaneous xenograft models, in which manipulated ovarian cancer cells were grown as tumors in animals, confirming that the axis influences tumor growth outside the controlled environment of a culture dish.

The clinical data add a layer of real-world relevance. Transcriptomic analysis, tissue microarrays and data from The Cancer Genome Atlas cohorts showed that USP12 is upregulated in ovarian cancer tissues compared with normal tissue, and that its expression positively correlates with TBC1D22A levels, consistent with the stabilizing relationship uncovered in the lab. More ominously, high USP12 expression predicted poorer overall survival and poorer progression-free survival in patients. In other words, the same molecular relationship that drives aggressiveness in laboratory models also tracks with worse outcomes in the clinic, strengthening the case that the axis is not an artifact of experimental conditions but a genuine feature of the disease.

For patients, the implications are cautiously encouraging. Ovarian cancer is often treated with surgery and platinum-based chemotherapy, and while PARP inhibitors have improved outlooks for some patients with homologous recombination deficiency, many tumors eventually become resistant. A deubiquitinase such as USP12 represents a different class of target, and DUB inhibitors have become an active frontier in drug development precisely because these enzymes can be drugged in ways that stabilize-or destabilize-key disease proteins. If the USP12-TBC1D22A axis proves essential in a broader set of ovarian tumors, blocking USP12 could deprive cancer cells of their stabilized TBC1D22A supply and dampen PI3K-AKT-mTOR signaling, potentially complementing existing therapies. The correlation between USP12 and survival also suggests it could serve as a prognostic marker, helping clinicians identify patients whose disease is likely to progress more rapidly.

There are, of course, important caveats. The study relied on cell lines, xenograft models and retrospective analysis of patient cohorts; prospective clinical validation, and demonstration that pharmacologically inhibiting USP12 benefits patients, remain future work. DUBs often have multiple substrates, so any therapeutic strategy would need to account for effects beyond TBC1D22A. Still, the work fills a genuine gap by identifying the first reported upstream regulatory pathway for TBC1D22A in ovarian cancer, and it does so with a methodologically thorough chain of evidence, from unbiased mass spectrometry through mechanistic biochemistry to animal models and human tissue data. As the authors conclude, the USP12-TBC1D22A axis may serve as a promising therapeutic target for ovarian cancer, and for a disease where new molecular handles are scarce, that promise is worth taking seriously.

Subject of Research: USP12-mediated deubiquitination and stabilization of TBC1D22A in ovarian cancer progression

Article Title: USP12 stabilizes TBC1D22A via deubiquitination to activate PI3K-AKT-mTOR signaling and promote ovarian cancer progression

Article References: Lv, X., Gong, R., Cai, X., & Guo, R. (2026). USP12 stabilizes TBC1D22A via deubiquitination to activate PI3K-AKT-mTOR signaling and promote ovarian cancer progression. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09027-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09027-8

Keywords: USP12, TBC1D22A, ovarian cancer, deubiquitinase, ubiquitin-proteasome pathway, PI3K-AKT-mTOR signaling, protein stability, Rab GTPase-activating protein, prognostic biomarker, xenograft model, Journal of Translational Medicine, cancer signaling